• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by HH&L Acquisition Co.

    2/6/24 1:47:53 PM ET
    $HHLA
    Medical Specialities
    Health Care
    Get the next $HHLA alert in real time by email
    SC 13G 1 HHL_Acquisition_Co.htm FILING HH&L ACQUISITION CO. Schedule 13G


     
    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. )*
     
    HH&L Acquisition Co. 

    (Name of Issuer)
     
    Class A ordinary shares, par value $0.0001 per share

    (Title of Class of Securities)
     
    G39714103

    (CUSIP Number)
     
    December 29, 2023

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         x  Rule 13d-1(b)
     
         o  Rule 13d-1(c)
     
         o  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  G39714103            
     
               
    1   NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
      JPMORGAN CHASE & CO.

    13-2624428
         
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)



      (a)   o
      (b)   o
         
    3   SEC USE ONLY
       
       
         
    4   CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware
           
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:  5   SOLE VOTING POWER
       
      401,967
         
    6   SHARED VOTING POWER
       
      0
         
    7   SOLE DISPOSITIVE POWER
       
      401,967
         
    8   SHARED DISPOSITIVE POWER
       
      0
         
    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      401,967
         
    10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      o
         
    11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      9.5 %
         
    12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      HC
     

    FOOTNOTES
       
     
     
     

     
     
    Item 1.


     
    (a)
    Name of Issuer
     
     
    HH&L Acquisition Co.


     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    Suite 2001-2002, 20/F, York House,
    The Landmark, 15 Queen's Road Central,
    Central, Hong Kong


    Item 2.


     
    (a)
    Name of Person Filing
     
     
    JPMORGAN CHASE & CO.


     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    383 Madison Avenue
    New York, NY 10179


     
    (c)
    Citizenship
     
     
    Delaware


     
    (d)
    Title of Class of Securities
     
     
    Class A ordinary shares, par value $0.0001 per share


     
    (e)
    CUSIP Number
     
     
    G39714103


     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:


     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).


     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).


     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).


     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).


     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);


     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);


     
    (g)
    x
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);


     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).


     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.


     
    (a)
    Amount beneficially owned: 401,967


     
    (b)
    Percent of class: 9.5 %


     
    (c)
    Number of shares as to which the person has:


     
    (i)
    Sole power to vote or to direct the vote: 401,967


     
    (ii)
    Shared power to vote or to direct the vote: 0


     
    (iii)
    Sole power to dispose or to direct the disposition of: 401,967


     
    (iv)
    Shared power to dispose or to direct the disposition of: 0


    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .
     
     
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    Not Applicable
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    J.P. Morgan Securities LLC
     
    Item 8.
    Identification and Classification of Members of the Group
     
    Not Applicable
     
    Item 9.
    Notice of Dissolution of Group
     
    Not Applicable
     
     
     

     
     
     
    Item 10.
    Certification
       
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     


    SIGNATURE


    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
      JPMORGAN CHASE & CO.

     
           
    Date: February 06, 2024
    By:
    /s/  Rachel Tsvaygoft  
        Name: Rachel Tsvaygoft  
        Title:  Vice President  
           
     
    Footnotes:


    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     



    Get the next $HHLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HHLA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HHLA
    SEC Filings

    See more
    • SEC Form 25-NSE filed by HH&L Acquisition Co.

      25-NSE - HH&L Acquisition Co. (0001824185) (Subject)

      2/23/24 10:50:57 AM ET
      $HHLA
      Medical Specialities
      Health Care
    • HH&L Acquisition Co. filed SEC Form 8-K: Other Events

      8-K - HH&L Acquisition Co. (0001824185) (Filer)

      2/7/24 11:57:39 AM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form PRE 14A filed by HH&L Acquisition Co.

      PRE 14A - HH&L Acquisition Co. (0001824185) (Filer)

      1/23/24 5:14:45 PM ET
      $HHLA
      Medical Specialities
      Health Care

    $HHLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by HH&L Acquisition Co.

      SC 13G - HH&L Acquisition Co. (0001824185) (Subject)

      2/14/24 5:09:41 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by HH&L Acquisition Co.

      SC 13G - HH&L Acquisition Co. (0001824185) (Subject)

      2/13/24 8:00:58 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by HH&L Acquisition Co. (Amendment)

      SC 13G/A - HH&L Acquisition Co. (0001824185) (Subject)

      2/12/24 4:26:19 PM ET
      $HHLA
      Medical Specialities
      Health Care

    $HHLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DiaCarta Receives Accreditation by the College of American Pathologists (CAP)

      PLEASNTON, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. ("DiaCarta"), a novel molecular diagnostic test developer for cancer and infectious diseases, today announced that it has received accreditation by the College of American Pathologists (CAP) for its CLIA certified lab. This accreditation is awarded to facilities that meet the high standards of quality, accuracy, and consistency in laboratory services required by CAP and underscores DiaCarta's leadership and commitment to excellence. "This CAP Accreditation is a tremendous accomplishment that signifies DiaCarta's commitment to excellence and I am proud of our team's dedication in support this major milestone," said Zheng 

      5/9/23 5:51:25 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • DiaCarta Announces Five Abstracts Accepted for Presentation at AACR Annual Meeting 2023

      Abstracts demonstrating XNA technology's improvements to assay sensitivity across different technology platforms and support for use in companion diagnostics (CDx) assay developmentAdditional abstracts to further support XNA technology's potential for use in minimal residual disease (MRD) monitoring of residual cancer cells PLEASANTON, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. ("DiaCarta"), a precision molecular diagnostics company, today announced that it will present five data posters at the American Association of Cancer Research (AACR) Annual Meeting 2023, which convenes in Orlando, Florida from April 14-19, 2023. The presentations will focus on how XNA can be used to

      4/16/23 2:00:00 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • DiaCarta Receives U.S. FDA Emergency Use Authorization for its Monkeypox Test Kit

      PLEASANTON, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. ("DiaCarta"), a precision molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its QuantiVirusTM MPXV test, which is a PCR test for the qualitative detection of DNA from monkeypox virus (MPXV) in lesion swabs collected from individuals suspected of monkeypox infection. The test is designed for use by authorized laboratories on the most popular qPCR instruments, including the Thermo Fisher (ABI) QuantStudio5, Thermo Fisher (ABI) 7500 Fast Dx, Bio-Rad CFX384, and Roche LightCycler 480 II Systems. QuantiVirusTM MPXV test targets two di

      1/12/23 8:30:00 AM ET
      $HHLA
      Medical Specialities
      Health Care

    $HHLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Highbridge Capital Management Llc sold $2,687,500 worth of Class A Ordinary Shares (250,000 units at $10.75) (SEC Form 4)

      4 - HH&L Acquisition Co. (0001824185) (Issuer)

      1/12/24 4:15:16 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form 3: New insider Highbridge Capital Management Llc claimed ownership of 500,000 units of Class A Ordinary Shares

      3 - HH&L Acquisition Co. (0001824185) (Issuer)

      8/15/23 4:30:21 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form 4 filed by HH&L Investment Co.

      4 - HH&L Acquisition Co. (0001824185) (Issuer)

      5/19/21 11:16:35 AM ET
      $HHLA
      Medical Specialities
      Health Care